Background The optimal duration of antibiotic therapy for patients with febrile neutropenia (FN) remains unknown. The Infectious Diseases Society of America recommends broad-spectrum intravenous antibiotic therapy until neutrophil count recovery
Search Results
Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia
William Alegria, Bernard L. Marini, Kevin Sellery Gregg, Dale Lee Bixby, Anthony Perissinotti, and Jerod Nagel
Myeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules
Betsy L. Althaus
-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors . Eur J Cancer 2006 ; 42 : 2433 – 2453 . 8. Scott SD Chrischilles EA Link BK . Days of prophylactic
Real-World Impact of a Decision Support Tool on Colony-Stimulating Factor Use and Chemotherapy-Induced Febrile Neutropenia Among Patients With Breast Cancer
Abiy Agiro, Andrea DeVries, Jennifer Malin, and Michael J. Fisch
Factors recommend febrile neutropenia (FN) prophylaxis using a colony-stimulating factor (CSF) when risk, based on the chemotherapy regimen and patient risk factors, is “high” (>20%). 7 CSF prophylaxis may also be considered based on patient risk factors
A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group
Gary H. Lyman and Marek S. Poniewierski
need to consider a range of risk factors for the occurrence and consequences of febrile neutropenia (FN), defined as body temperature >38.5°C or 2 consecutive measurements >38°C with an absolute neutrophil count <0.5 × 10 9 /L. Risk Factors for FN
Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy
Douglas W. Blayney, Nicole M. Kuderer, Alice Kate Cummings Joyner, John Jarvis, Dominic Nunag, Jasmine Wells, Lan Huang, Ramon Mohanlal, and Gary H. Lyman
Background Patients with breast cancer treated with myelosuppressive chemotherapy are at an increased risk of developing febrile neutropenia (FN), a medical emergency characterized by the occurrence of fever during a period of significant
QIM19-129: Utilization of Electronic Medical Record to Improve Outcomes in the Treatment of Febrile Neutropenia
Anna M. Gibson and Claire Sutherby
Introduction: Chemotherapy-induced febrile neutropenia is a medical emergency. Delays in time to appropriate broad spectrum antibiotic therapy significantly increase morbidity and mortality. The purpose of this project is to improve outcomes in
Timing of Initial Antibiotic Treatment for Febrile Neutropenia in the Emergency Department: The Need for Evidence-Based Guidelines
Demetrios N. Kyriacou, Borko Jovanovic, and Olga Frankfurt
several studies that illustrate the delayed times to initial antibiotic treatment for adults with FN in EDs Table 1 Current Guidelines for Timing of Initial Antibiotic Treatment of Adult Patients With Febrile Neutropenia worldwide, indicating
BPI19-010: Febrile Neutropenia Induced by Chemotherapy: Impact of Risk Re-Stratification
David da Silva Dias, Catarina Jorge, Mafalda Baptista, Ana Júlia Arede, Paulo Luz, Tânia Madureira, and Beatriz Gosalbez
Introduction: Febrile neutropenia (FN) induced by chemotherapy (ChT) arises until 6 weeks after the last cycle, usually between 5 and 10 days post-ChT. Infection risk is 20%–30%. It is difficult to stratify patients with low risk of complications
The Utility of Routine Chest Radiography in the Initial Evaluation of Adult Patients With Febrile Neutropenia Patients Undergoing HSCT
Deborah S. Yolin-Raley, Ibiayi Dagogo-Jack, Heidi B. Niell, Robert J. Soiffer, Joseph H. Antin, Edwin P. Alyea III, and Brett E. Glotzbecker
febrile neutropenia workup. As of July 2012, CXRs were ordered according to physician preference, instead of according to strict adherence to guidelines. Most of the CXRs ordered for the inpatients were obtained within 24 hours of initiation of antibiotics
Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao
Background Febrile neutropenia (FN) is a serious adverse effect of myelosuppressive chemotherapy that can affect treatment by contributing to dose delays and reductions. 1 FN often requires hospitalization and incurs a significant healthcare
